<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="topic" /><meta name="keywords" content="Cardiovascular disease: myocardial infarction: non-ST-segment elevation; Myocardial infarction: non-ST-segment elevation; Angina: unstable; Aspirin: angina; Angina: management: aspirin; Angina: management: clopidogrel; Clopidogrel; Angina: management: heparins; Eptifibatide; Tirofiban; Angina: management: aspirin; Aspirin: angina" /><meta name="IX" content="Cardiovascular disease: myocardial infarction: non-ST-segment elevation; Myocardial infarction: non-ST-segment elevation; Angina: unstable; Aspirin: angina; Angina: management: aspirin; Angina: management: clopidogrel; Clopidogrel; Angina: management: heparins; Eptifibatide; Tirofiban; Angina: management: aspirin; Aspirin: angina" /><title>Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI): British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="204269.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="204269.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=204269.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a> &gt; <a href="60549.htm">2.10 Stable angina, acute coronary syndromes, and fibrinolysis</a> &gt; <a href="60552.htm">2.10.1 Management of stable angina and acute coronary syndromes</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="204266.htm" title="Previous: Acute coronary syndromes">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="204270.htm" title="Next: Management of ST-segment elevation myocardial infarction (STEMI)">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_204269">Management of unstable angina and non-ST-segment elevation
myocardial infarction (NSTEMI)</h1><?highlighter on?><div id="pC" class="jN"><p>These conditions are managed similarly; the aims of management are
to provide supportive care and pain relief during the acute attack
and to prevent further cardiac events and death. For advice on the
management of patients with acute ST-segment elevation myocardial
infarction (STEMI), see <a title="BNF:topic: Management of ST-segment elevation myocardial infarction" href="204270.htm#_204270">below</a>.</p><div class="cAZ"><h2>Initial management</h2> <p class="cAX"><b>Oxygen</b> (<a title="section: Oxygen" href="3058.htm#_3058">section
3.6</a>) should be administered if there is evidence of hypoxia,
pulmonary oedema, or continuing myocardial ischaemia; hyperoxia should
be avoided and particular care is required in patients with chronic
obstructive airways disease.</p><p><b>Nitrates</b> (<a title="sub-section: Nitrates" href="2615.htm#_2615">section 2.6.1</a>) are used to relieve ischaemic pain. If sublingual
glyceryl trinitrate is not effective, intravenous or buccal glyceryl
trinitrate or intravenous isosorbide dinitrate is given. If pain continues, <b>diamorphine</b> or <b>morphine</b> (<a title="monograph: DIAMORPHINE HYDROCHLORIDE" href="3521.htm#_3521">section 4.7.2</a>) can be given by slow intravenous
injection; an antiemetic such as metoclopramide should also be given
(<a title="BNF:monograph: METOCLOPRAMIDE HYDROCHLORIDE" href="3431.htm#_3431">section 4.6</a>).</p><p><b>Aspirin</b> (chewed or dispersed in water) is given for its antiplatelet effect
in a dose of 300 mg (<a title="section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>). If aspirin is given before arrival
at hospital, a note saying that it has been given should be sent with
the patient. <b>Clopidogrel</b> in a
dose of 300 mg (or 600 mg [unlicensed] if used prior to percutaneous
coronary intervention) should also be given (see <a title="section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>). <b>Prasugrel</b>, in
a dose of 60 mg, is an alternative to clopidogrel in certain patients
undergoing percutaneous coronary intervention (see <a title="BNF:target-block: nice prasugrel 2009" href="2802.htm#_204276">NICE guidance</a>). <b>Ticagrelor</b>, in a dose of 180 mg, is also an alternative to clopidogrel (see <a title="BNF:target-block: Ticagrelor NICE guidance" href="2802.htm#_218765">NICE guidance</a>). Patients should also receive
either <b>unfractionated heparin</b>, a <b>low molecular weight
heparin</b>, or <b>fondaparinux</b> (<a title="sub-section: Parenteral anticoagulants" href="2761.htm#_2761">section 2.8.1</a>).</p><p>Patients without contra-indications should receive <b>beta-blockers</b> (<a title="section: Beta-adrenoceptor blocking drugs" href="2455.htm#_2455">section 2.4</a>) which should
be continued indefinitely. In patients without left ventricular dysfunction
and in whom beta-blockers are inappropriate, <b>diltiazem</b> or <b>verapamil</b> can be given (<a title="sub-section: Calcium-channel blockers" href="2616.htm#_2616">section 2.6.2</a>).</p><p>The glycoprotein IIb/IIIa inhibitors <b>eptifibatide</b> and <b>tirofiban</b> (<a title="section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>) can be used (with aspirin and
unfractionated heparin) for unstable angina or for NSTEMI in patients
at a high risk of either myocardial infarction or death.</p><p>In intermediate- and high-risk patients, abciximab, eptifibatide,
or tirofiban can also be used with aspirin and unfractionated heparin
in patients undergoing percutaneous coronary intervention, to reduce
the immediate risk of vascular occlusion. In intermediate- and high-risk
patients in whom early intervention is planned, bivalirudin (<a title="BNF:monograph: BIVALIRUDIN" href="129014.htm#_129014">section 2.8.1</a>) can be considered as an alternative
to the combination of a glyocprotein IIb/IIIa inhibitor plus a heparin.</p><p>Revascularisation procedures are often appropriate for patients
with unstable angina or NSTEMI; see <a title="BNF:target-block: Antiplatelet drugs in coronary stenting" href="2802.htm#_208000">section 2.9</a> for the
use of antiplatelet drugs in patients undergoing coronary stenting.</p></div><div class="cAZ"><h2>Long-term management</h2> <p class="cAX">The need for long-term angina
treatment or for coronary angiography should be assessed. Most patients
will require standard angina treatment (see management of stable angina,
above) to prevent recurrence of symptoms.</p></div><div id="_204165"><div class="cAZ"><h2>Prevention of cardiovascular events</h2> <p class="cAX">Patients with
stable angina, unstable angina, or NSTEMI should be given advice and
treatments to reduce their cardiovascular risk. The importance of
life-style changes, especially stopping smoking, should be emphasised. <b>Aspirin</b> should be given indefinitely in a dose of
75 mg daily. Antihypertensive treatment should be initiated if appropriate
(see <a title="BNF:section: Hypertension and heart failure" href="2534.htm#_2534">section 2.5</a>), and a <b>statin</b> (<a title="BNF:monograph-family: Statins" href="33422.htm#_33422">section 2.12</a>) should also be given.</p><p>In patients with stable angina, addition of an <b>ACE inhibitor</b> (<a title="BNF:sub-sub-section: Angiotensin-converting enzyme inhibitors" href="2578.htm#_2578">section 2.5.5.1</a>) should
be considered for patients with diabetes (and should be continued
if indicated for a co-morbidity).</p><p>In patients with unstable angina or NSTEMI, clopidogrel (<a title="BNF:section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>) is given, in combination with
aspirin, for up to 12 months—most benefit occurs during the first
3 months. Prasugrel or ticagrelor are alternatives to clopidogrel
in certain patients (see <a title="BNF:section: Antiplatelet drugs" href="2802.htm#_2802">section 2.9</a>). An ACE inhibitor should also
be given.</p></div></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="204266.htm">Previous: Acute coronary syndromes</a> | <a class="top" href="204269.htm#">Top</a> | <a accesskey="]" href="204270.htm">Next: Management of ST-segment elevation myocardial infarction (STEMI)</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>